Cannvas MedTech Inc. (“Cannvas” or the “Company”) (CSE:MTEC), a leading business technology company within the cannabis space, is pleased to announce that its first cannabis-centric service offering to the public will be Cannvas.me, with an anticipated launch in Q3 of 2018. An innovative approach at placing cannabis education at the forefront of this service offering, Cannvas.me is a scalable and comprehensive solution for the global cannabis community offering interactive tools and physician-backed content to all audiences who wish to learn about healthcare through cannabis.

“Education without the outside influence is our primary mission with Cannvas.me,” said Shawn Moniz, Chief Executive Officer, Cannvas MedTech Inc. “Cannvas.me places the needs of its users first, in their pursuit of alternative healthcare, by educating them on treatments and support of a healthy and responsible lifestyle through the use of cannabis. Being independent and not financially sponsored by the licensed producer community, or other entities, helps ensure information is produced and maintained in an unbiased fashion, free from outside influence.”


Representing the voice of its audience’s needs, Cannvas intends to work with the global academic, government, and policy making communities to help inform educators on the future face of consumers needs and wants within the cannabis space.

“The response to the concept of a centralized, unbiased, credible source for cannabis information and education has been overwhelming,” said Steve Loutskou, Chief Operating Officer, Global Markets, Cannvas MedTech Inc. “With cannabis related policies being introduced around the world, there continues to be a customer-facing information void with respect to credible health and wellness benefits of this growing alternative medicine. More and more research is being conducted on the benefits of medical cannabis, but vague and anecdotal information continues to be the norm.”

The free to use platform utilizes machine learning algorithms and artificial intelligence (AI) to contextualize and adapt to users of the platform, ensuring that the content they are served will be geographically and personally relevant to them. Furthermore, the contextual AI-supported service ensures that each customer’s journey is built upon their last interaction, giving individuals a uniquely progressive experience. The site will feature innovative tools such as educational learning modules in its Cannvas University, an interactive Cannvas Strain Matcher service that educates audiences with specific ailments, and Cannvas Culinary, for those wishing to learn about the culinary approach to treatments.

About Cannvas MedTech Inc.
Cannvas MedTech is a leading business technology company within the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted onwww.sedar.com.

SOURCE Cannvas MedTech Inc.

Click here to connect with Cannvas MedTech Inc. (CSE:MTEC) for an Investor Presentation

Source: www.newswire.ca

Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry

Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:

Nextleaf Comments on Financial Results from Q1 Financials

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.

The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.

Keep reading... Show less

Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues

FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million

Keep reading... Show less

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

Keep reading... Show less